The cost-effectiveness of Dacomitinib in comparison with Gefitinib in patients with classical EGFR activating non-small cell lung cancer

Additional Metadata
Keywords	Health technology assessment;cost effectiveness;non-small cell lung cancer
Thesis Advisor	Heine, R.J.S.D.
Persistent URL	hdl.handle.net/2105/62485
Series	Master Health Economics, Policy and Law
Organisation	Erasmus School of Health Policy & Management
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Haan, N.V. de. (2021, July 7). The cost-effectiveness of Dacomitinib in comparison with Gefitinib in patients with classical EGFR activating non-small cell lung cancer. Master Health Economics, Policy and Law. Retrieved from http://hdl.handle.net/2105/62485

Publication